Esperion Therapeutics (ESPR) News Today $1.20 -0.01 (-0.83%) Closing price 06/12/2025 04:00 PM EasternExtended Trading$1.12 -0.08 (-6.25%) As of 07:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Research Analysts Set Expectations for ESPR FY2026 EarningsJune 13 at 3:21 AM | americanbankingnews.comResearch Analysts Offer Predictions for ESPR FY2026 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Esperion Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will postJune 11 at 9:03 AM | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hoJune 11 at 1:38 AM | marketbeat.comTraders Purchase High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR)June 10 at 1:01 AM | americanbankingnews.comTraders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors bought 2,720 call options on the company. This represents an increase of approximately 124% compared to the typical daily volume of 1,216 call options.June 9, 2025 | marketbeat.comWhat is Zacks Research's Forecast for ESPR Q2 Earnings?June 8, 2025 | americanbankingnews.comQ2 EPS Forecast for Esperion Therapeutics Lifted by AnalystEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for Esperion Therapeutics in a report issued on Wednesday, June 4th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical companJune 6, 2025 | marketbeat.comMillennium Management LLC Has $1.83 Million Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Millennium Management LLC lowered its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 75.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 829,885 shares of the biopharmJune 3, 2025 | marketbeat.comDeutsche Bank AG Sells 1,393,852 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Deutsche Bank AG reduced its position in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 89.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 166,220 shares of the biopharmJune 1, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Bank of America Corp DEBank of America Corp DE increased its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 45.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,629,980 shares of the biopharmaceutical company'sJune 1, 2025 | marketbeat.comZacks Research Has Pessimistic Outlook of ESPR Q2 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Zacks Research reduced their Q2 2025 earnings estimates for Esperion Therapeutics in a report issued on Tuesday, May 27th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earningsMay 31, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Lifted by Nuveen Asset Management LLCNuveen Asset Management LLC raised its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 48.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 3,119,253 shares of the biopharmaceutical company's stock after buying an additional 1,020May 31, 2025 | marketbeat.comWhat is Zacks Research's Forecast for ESPR FY2027 Earnings?Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities researchers at Zacks Research boosted their FY2027 earnings per share (EPS) estimates for Esperion Therapeutics in a research note issued on Tuesday, May 27th. Zacks Research analyst K. Das now anticipates that the biopharmaceuticMay 30, 2025 | marketbeat.comWoodline Partners LP Has $3.31 Million Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Woodline Partners LP cut its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 33.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,503,746 shares of the biopharmaceutical company's stock afterMay 27, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Rating of "Moderate Buy" by BrokeragesShares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given aMay 19, 2025 | marketbeat.comEsperion Settles Patent Litigation With Micro Labs For Generic NexletolMay 14, 2025 | nasdaq.comEsperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040May 12, 2025 | globenewswire.comHC Wainwright Issues Pessimistic Outlook for ESPR EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a report released on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company willMay 11, 2025 | marketbeat.comEsperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor ConferenceMay 9, 2025 | theglobeandmail.comEsperion Therapeutics (NASDAQ:ESPR) Price Target Lowered to $4.00 at Needham & Company LLCNeedham & Company LLC dropped their target price on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Wednesday.May 9, 2025 | marketbeat.comEsperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor ConferenceMay 9, 2025 | globenewswire.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 8, 2025 | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) Announces Earnings ResultsEsperion Therapeutics (NASDAQ:ESPR - Get Free Report) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03).May 8, 2025 | marketbeat.comEsperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in CanadaMay 8, 2025 | globenewswire.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2025 Earnings Call TranscriptMay 7, 2025 | msn.comEsperion Therapeutics Inc (ESPR) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...May 7, 2025 | finance.yahoo.comEsperion Reports First Quarter 2025 Financial ResultsMay 6, 2025 | finance.yahoo.comEsperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comZacks Research Has Optimistic Outlook of ESPR Q1 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Zacks Research boosted their Q1 2026 earnings estimates for shares of Esperion Therapeutics in a research note issued to investors on Monday, April 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will pMay 2, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Reduced by Renaissance Technologies LLCRenaissance Technologies LLC trimmed its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 36.7% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 578,800 shares of the biopharmaceutical company's stock after selling 335,300 shares durMay 2, 2025 | marketbeat.comResearch Analysts Set Expectations for ESPR FY2027 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Zacks Research boosted their FY2027 earnings estimates for shares of Esperion Therapeutics in a research note issued to investors on Monday, April 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will poMay 1, 2025 | marketbeat.comEsperion Therapeutics (ESPR) Projected to Post Quarterly Earnings on TuesdayEsperion Therapeutics (NASDAQ:ESPR) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-esperion-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) is Indaba Capital Management L.P.'s 10th Largest PositionIndaba Capital Management L.P. lowered its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 91.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,000,000 shares of the biophaApril 30, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $5.00 target price on shares of Esperion Therapeutics in a research note on Friday.April 27, 2025 | marketbeat.comEsperion Therapeutics' (ESPR) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Friday.April 27, 2025 | marketbeat.comEsperion to Participate in The Citizens Life Sciences ConferenceApril 25, 2025 | globenewswire.comEsperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025April 24, 2025 | globenewswire.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one hasApril 24, 2025 | marketbeat.comEsperion to Report First Quarter 2025 Financial Results on May 6April 23, 2025 | finance.yahoo.comEsperion Therapeutics, Inc. (ESPR) Stock ForecastsApril 23, 2025 | ca.finance.yahoo.comEsperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...April 21, 2025 | finance.yahoo.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Holdings Lifted by JPMorgan Chase & Co.JPMorgan Chase & Co. raised its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 18.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,454,216 shares of the biopharmApril 20, 2025 | marketbeat.comWasatch Advisors LP Purchases 1,136,245 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wasatch Advisors LP boosted its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 4.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,482,258 shares of the biopharmApril 18, 2025 | marketbeat.comVanguard Group Inc. Has $25.78 Million Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Vanguard Group Inc. cut its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 10.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,715,748 shares of the biopharmaceutical company's stock afteApril 16, 2025 | marketbeat.comCenterBook Partners LP Has $2.87 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)CenterBook Partners LP lowered its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 58.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,306,259 shares of the biopharmaApril 12, 2025 | marketbeat.comEsperion to host R&D Day to highlight cardiometabolic pipelineApril 11, 2025 | markets.businessinsider.comEsperion Therapeutics' (ESPR) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $5.00 price objective on shares of Esperion Therapeutics in a report on Tuesday.April 10, 2025 | marketbeat.comEsperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025April 10, 2025 | globenewswire.comEsperion (ESPR) Gets a Buy from NeedhamApril 8, 2025 | markets.businessinsider.comEsperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?April 3, 2025 | msn.com Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Media Mentions By Week ESPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼1.030.88▲Average Medical News Sentiment ESPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼154▲ESPR Articles Average Week Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Pharvaris News Today uniQure News Today Praxis Precision Medicines News Today Ardelyx News Today LENZ Therapeutics News Today Oculis News Today Zymeworks News Today Intellia Therapeutics News Today Nuvation Bio News Today ArriVent BioPharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ESPR Stock Free ESPR Stock Alerts